First patients receive experimental 'Living Drug' for tough cancers
Disease control
Ongoing
This is a first-in-human study to test the safety and find the right dose of a new cell therapy called BOXR1030. It is for adults with advanced solid tumors (like certain liver, lung, skin, and soft tissue cancers) that have a specific protein marker called GPC3. Doctors will col…
Phase: PHASE1, PHASE2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC